Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
Status:
Terminated
Trial end date:
2021-08-24
Target enrollment:
Participant gender:
Summary
This is a phase 1 dose escalation study to characterize the feasibility, safety and
tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly
doses for women with platinum resistant high grade serous adenocarcinoma of the ovary,
primary peritoneum, or fallopian tube, and subjects with peritoneal mesothelioma with
recurrence after prior chemotherapy. The study will also assess multiple cycles of treatment
and adding preconditioning with cyclophosphamide.